MRNA Vaccine And Therapeutics Market Size 2032
mRNA Vaccine and Therapeutics Market Size and Forecast (2025 - 2032), By Type (Vaccines, Therapeutics), By Application (Infectious Diseases, Cancer, Genetic Disorders, Others), By Route of Administration (Intramuscular, Intravenous, Others), By End-user (Hospitals, Specialty Clinics, Research Institutes, Others), and Geography.
Report Highlights:
With a CAGR of 17.1%, the global mRNA Vaccine and Therapeutics Market is predicted to grow from 2025 to 2032. The projected market value in 2022 is USD 46.7 billion; by 2032 it is expected to have increased to USD 137.2 Billion. Thanks to better healthcare infrastructure and large R&D spending, North America now dominates the market.
Mostly driven by the successful development and deployment of mRNA-based COVID-19 vaccines, the mRNA vaccination and therapeutics company has lately experienced until unheard-of growth. This finding opens fresh chances for mRNA technology to address more disorders beyond viral ones. Constant research and development efforts are helping mRNA systems to treat cancer, genetic disorders, and other chronic conditions to be more widely used. Pharmaceutical companies and academic institutes are collaborating more to speed discovery and bring new mRNA-based medicines to the market.
Market Dynamics:
Market Trend: widening of therapeutic fields
Emphasizing its flexibility and promise, the mRNA technology platform is rapidly expanding beyond of vaccines into new therapeutic domains. Originally most recognized from COVID-19 immunizations, mRNA-based treatments are under research for cancer, uncommon genetic defects, and autoimmune diseases. This development is driven by the ability of the technology to produce very exact proteins in the body since it may offer more targeted and effective treatments than traditional drugs. Because mRNA therapeutics are also under development for protein replacement treatments in genetic disorders, which offers fresh hope for hitherto incurable diseases, personalized cancer vaccinations where mRNA may be tailored to a tumor profile especially thrill researchers. Drawn to this paradigm and making significant investments to drive invention and expand the mRNA-based candidate pipeline across many disease domains, both big pharmaceutical companies and biotech startups find appeal in this approach.
Market Driver: technical advancements in mRNA stability and delivery
Technological advancements in mRNA delivery techniques and stability are main drivers fueling the growth of the mRNA vaccines and therapeutics market. Main challenges in mRNA-based treatments have been its fragility and efficient dispersion to target cells. mRNA's stability and cellular absorption have been much raised by recent developments in lipid nanoparticle (LNP) technology, thereby boosting the efficacy of mRNA-based treatments. These advances have not only improved the shelf life of mRNA therapies and vaccines but also their dispersion capacity, therefore making them more useful for public consumption. Furthermore, discoveries in altering mRNA structures to reduce immunogenicity and increase protein expression have general application for this technology. The general effectiveness of mRNA-based treatments has increased as more efficient protein production in target cells arising from the capacity to alter mRNA sequences and enhance codon utilization results. More research focus and funding generated by these technical developments are helping to produce new mRNA products in many different therapeutic areas.
Market Restraint: High expenses in development and manufacturing
The great expenses related to the manufacturing and development of mRNA-based vaccines and therapeutics greatly restrict market expansion. mRNA technology is so complex that certain facilities, techniques, and understanding are required, which drives large upfront research and development expenses. Every one of the various phases in the manufacturing process—in vitro transcription, purification, formulation using lipid nanoparticles, and so on—requires thorough quality control practices. These factors help to clarify why some vaccines and medications have larger manufacturing costs than others. Moreover adding to the overall cost are the needs for ultra-cold chain storage and distribution for specific mRNA products, which can limit availability in places without appropriate infrastructure. The high costs can cause premium pricing for mRNA-based products, thereby restricting market penetration especially for non-emergency usage or in underdeveloped countries. While economies of scale and technical advancements could finally assist to reduce costs, the present high expenses remain a primary barrier to more adoption and market extension of mRNA vaccines and therapies.
Segment Analysis:
mRNA usage are largely connected to infectious diseases.
The category of infectious diseases today dominates the mRNA vaccination and treatments market thanks in significant part to their unmatched performance as mRNA-based COVID-19 vaccines are. Many components underlining the advantages of mRNA technology in the battle against infectious diseases contribute to explain the prominence of this field. First of all, the rapid proliferation of mRNA vaccines during the COVID-19 epidemic demonstrated the ability of the platform to respond to fresh health concerns. Dealing with new pandemics or epidemics depends on this speed absolutely. Second, especially against COVID-19, mRNA vaccinations have shown remarkable success rates, therefore inspiring hope in the capacity of the technology for other infectious diseases. One of the main advantages of the often shifting landscape of infectious diseases is the versatility of mRNA platforms that enables fast adjustments to target new variants or strains. Moreover under research are mRNA-based vaccines for other challenging infectious diseases including the Zika virus, HIV, and influenza. The achievement in COVID-19 has accelerated research and funding in these domains, maybe leading to breakthroughs in diseases long neglected by efficient vaccination. The segment on infectious diseases is expected to remain dominant in not too distant future as new mRNA-based vaccines pass clinical testing and maybe obtain market approval for other diseases.
Regional Outlook:
Adoption of mRNA technologies starts from North America.
Driven by many key factors that place North America at the forefront of mRNA technology adoption and development, the region today rules the global mRNA vaccine and therapeutics industry. Especially the United States has been a hub for creative mRNA technology development; many of the leading biotechnology companies and labs in the nation start from here. mRNA platforms have advanced rapidly thanks to this mix of tools and knowledge. Large research and development investment as well as the area's robust healthcare infrastructure have accelerated clinical development and commercialization of mRNA-based therapies. Moreover, as the COVID-19 pandemic shows, fast-track licencing processes and good legislative frameworks have let mRNA vaccines and therapies hit the market more rapidly. Early adoption of creative medical technologies and high levels of healthcare expenditure benefit North America as well, which clarifies the rapid acceptance of mRNA-based products. Even more in the field, major pharmaceutical corporations and their interactions with biotech companies have spurred innovation and commercial growth. As mRNA technology expands into new therapeutic domains outside infectious diseases, North America is positioned to maintain its leadership in the market, so supporting constant research, development, and commercialization of fresh mRNA-based medicines.
Competitive Landscape:
The mRNA vaccine and therapeutics industry is characterized by intense rivalry and quick innovation as a mix of seasoned pharmaceutical giants and specialized biotech companies fight for market domination. Important players are significantly supporting research and development to expand their mRNA platforms and pipelines into numerous therapeutic areas. Strategic alliances and partnerships are very common since companies want to combine knowledge in mRNA technology, drug delivery systems, and specific disease areas. Notable merger and acquisition activity on the market has come from larger pharmaceutical companies purchasing or investing in smaller biotech startups to gain proprietary mRNA technologies. Another area of focus for companies striving to meet the growing demand for mRNA-based goods is increasing manufacturing capacity. The competitive situation is rapidly being changed by new rivals bringing innovative concepts to mRNA design, distribution, and use. As the sector shifts outside vaccines into drugs, competition in sectors such cancer immunotherapy and rare genetic illnesses is rising. Intellectual property rights and patent portfolios are therefore very important for competitive positioning since companies want to protect their ideas and ensure market exclusiveness.
Major Players:
-
Moderna, Inc.
-
BioNTech SE
-
CureVac N.V.
-
Translate Bio (acquired by Sanofi)
-
Arcturus Therapeutics Holdings Inc.
-
eTheRNA
-
Ethris GmbH
-
Gennova Biopharmaceuticals Limited
-
GlaxoSmithKline plc
-
Pfizer Inc.
-
Sanofi S.A.
-
Argos Therapeutics, Inc.
Key Developments:
-
Moderna disclosed in August 2023 positive Phase 3 trial results for its mRNA-based seasonal influenza vaccination candidate. FDA clearance for BioNTech and Pfizer's mRNA-based immunization targeted at new COVID-19 mutations in March 2024
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2025- 2032)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global mRNA Vaccine and Therapeutics Market (2025 – 2032)
3.2. Global mRNA Vaccine and Therapeutics Market (2025 – 2032)
3.2.1. Market Segment By Type (2025 – 2032)
3.2.2. Market Segment By Application (2025 – 2032)
3.2.3. Market Segment By Route of Administration (2025 – 2032)
3.2.4. Market Segment By End-user (2025 – 2032)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Expansion into new therapeutic areas
4.1.2. Personalized medicine approaches
4.1.3. Combination therapies with mRNA
4.2. Market Drivers
4.2.1. Technological advancements in mRNA delivery and stability
4.2.2. Increasing investment in mRNA research
4.2.3. Growing prevalence of chronic diseases
4.3. Market Restraints
4.3.1. High development and production costs
4.3.2. Regulatory challenges
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY TYPE (MARKET VALUE (US$ MILLION) – 2025-2032*)
5.1. Vaccines
5.2. Therapeutics
6. BY APPLICATION
6.1. Infectious Diseases
6.2. Cancer
6.3. Genetic Disorders
6.4. Others
7. BY ROUTE OF ADMINISTRATION
7.1. Intramuscular
7.2. Intravenous
7.3. Others
8. BY END-USER
8.1. Hospitals
8.2. Specialty Clinics
8.3. Research Institutes
8.4. Others
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITIVE LANDSCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. Moderna, Inc.
12.2. BioNTech SE
12.3. CureVac N.V.
12.4. Translate Bio (acquired by Sanofi)
12.5. Arcturus Therapeutics Holdings Inc.
12.6. eTheRNA
12.7. Ethris GmbH
12.8. Gennova Biopharmaceuticals Limited
12.9. GlaxoSmithKline plc
12.10. Pfizer Inc.
12.11. Sanofi S.A.
12.12. Argos Therapeutics, Inc. (*LIST NOT EXHAUSTIVE)
13. MARKET OPPORTUNITIES
By Type:
- Vaccines
- Therapeutics
By Application:
- Infectious Diseases
- Cancer
- Genetic Disorders
- Others
By Route of Administration:
- Intramuscular
- Intravenous
- Others
By End-user:
- Hospitals
- Specialty Clinics
- Research Institutes
- Others
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511